Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Insulin-degrading enzyme higher in subjects with metabolic syndrome.
Sofer Y, Nash Y, Osher E, Fursht O, Goldsmith G, Nahary L, Shaklai S, Tordjman KM, Serebro M, Touati EB, Yacobi Bach M, Marcus Y, Tal B, Sack J, Shefer G, Margaliot M, Landis N, Goldiner I, Abu Ahmad W, Stern N, Benhar I, Frenkel D. Sofer Y, et al. Among authors: margaliot m. Endocrine. 2021 Feb;71(2):357-364. doi: 10.1007/s12020-020-02548-2. Epub 2021 Jan 4. Endocrine. 2021. PMID: 33398768
Multidisciplinary Treatment of the Metabolic Syndrome Lowers Blood Pressure Variability Independent of Blood Pressure Control.
Marcus Y, Segev E, Shefer G, Sack J, Tal B, Yaron M, Carmeli E, Shefer L, Margaliot M, Limor R, Gilad S, Sofer Y, Stern N. Marcus Y, et al. Among authors: margaliot m. J Clin Hypertens (Greenwich). 2016 Jan;18(1):19-24. doi: 10.1111/jch.12685. Epub 2015 Sep 26. J Clin Hypertens (Greenwich). 2016. PMID: 26408073 Free PMC article.
On the gain of entrainment in the n-dimensional ribosome flow model.
Ofir R, Kriecherbauer T, Grüne L, Margaliot M. Ofir R, et al. Among authors: margaliot m. J R Soc Interface. 2023 Feb;20(199):20220763. doi: 10.1098/rsif.2022.0763. Epub 2023 Feb 8. J R Soc Interface. 2023. PMID: 36751928 Free PMC article.
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
Das Pradhan A, Glynn RJ, Fruchart JC, MacFadyen JG, Zaharris ES, Everett BM, Campbell SE, Oshima R, Amarenco P, Blom DJ, Brinton EA, Eckel RH, Elam MB, Felicio JS, Ginsberg HN, Goudev A, Ishibashi S, Joseph J, Kodama T, Koenig W, Leiter LA, Lorenzatti AJ, Mankovsky B, Marx N, Nordestgaard BG, Páll D, Ray KK, Santos RD, Soran H, Susekov A, Tendera M, Yokote K, Paynter NP, Buring JE, Libby P, Ridker PM; PROMINENT Investigators. Das Pradhan A, et al. N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5. N Engl J Med. 2022. PMID: 36342113 Clinical Trial.
47 results